en · de · es · fr · pt
aod-9604-notes.peptides6579.com › Info › Regulatory And Analytical Context — Field Notes

Regulatory And Analytical Context — Field Notes

By Editorial Desk · published 2025-10-18 · last reviewed 2025-11-01 · Info

If you have been reading about anti-doping and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Updated 2025-11-01. Numbers and descriptions here follow the published literature rather than marketing material.

Regulatory and Analytical Context

Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.

In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.

Identity And Research Background

AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.

AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.

Aod-9604 at a glance

PropertyValueNotes
Regulatory statusNot approved as a medicineStatus varies by country; prohibited in sport.
Common storage temperature2–8 °C for lyophilized powderProtect from light and moisture; follow supplier instructions.
Typical analytical methodLC-MS/MSUsed for identification and quantification in biological samples.
Purity assessmentHPLC and mass spectrometryReverse-phase HPLC is common for peptide purity.
Common synonymsAOD9604; hGH 176-191 fragmentNaming conventions differ across studies.

Background and Development History

Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.

AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.

Related pages on this site

Research and Regulatory Context

Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.

AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.

Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.

Identity and Molecular Context

Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.

AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.

The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.

Further detail

=== Spectroscopy === In quantum mechanics, the energy levels of electrons in atoms depend on the reduced mass of the system of electron and nucleus. For a hydrogen atom, the role of reduced mass is most simply seen in the Bohr model of the atom, where the reduced mass appears in a simple calculation of the Rydberg constant and Rydberg equation, but the reduced mass also appears in the Schrödinger equation, and the Dirac equation for calculating atomic energy levels. The reduced mass of the system in these equations is close to the mass of a single electron, but differs from it by a small amount about equal to the ratio of mass of the electron to the nucleus. For 1H, this amount is about ⁠1837/1836⁠, or 1.000545, and for 2H it is even smaller: ⁠3671/3670⁠, or 1.000272. The energies of electronic spectra lines for 2H and 1H therefore differ by the ratio of these two numbers, which is also very close to 1.000272. The wavelengths of all deuterium spectroscopic lines are shorter than the corresponding lines of light hydrogen, by 0.0272%. In astronomical observation, this corresponds to a blue Doppler shift of 0.0272% of the speed of light, or 81.6 km/s. The differences are much more pronounced in vibrational spectroscopy such as infrared spectroscopy and Raman spectroscopy, and in rotational spectra such as microwave spectroscopy because the reduced mass of the deuterium is markedly higher than that of protium. In nuclear magnetic resonance spectroscopy, deuterium has a very different NMR frequency (e.g. 61 MHz when protium is at 400 MHz) and is much less sensitive.

=== Storage === All vegetables benefit from proper post harvest care. A large proportion of vegetables and perishable foods are lost after harvest during the storage period. These losses may be as high as thirty to fifty percent in developing countries where adequate cold storage facilities are not available. The main causes of loss include spoilage caused by moisture, moulds, micro-organisms, and vermin.

Paddy Considine was cast as Viserys in October 2020 for House of the Dragon, a prequel to Game of Thrones. In an interview with Winter is Coming, showrunner Ryan Condal explained that Considine was the first choice for the role of Viserys, praising him as an "incredibly gifted actor" who had experience in "everything from comedy to dark drama". Considine was in "disbelief" upon finding out that he was being offered the role, as he believed that the entertainment industry had "at large had only ever seen him as the working-class striver he made his name playing in the 2000s". He was glad to take on the new role, as he thought himself "capable of so much more than what I was being given to play with", and felt that "he could finally showcase the full breadth of his talent." Considine used the experience of witnessing his late father's declining health from cancer as an inspiration in portraying the physical decline of a frail Viserys in "The Lord of the Tides". He described his father as dealing with "gargling sounds, fighting for breath, and... being high on painkilling drugs and things like that", and added these elements to Viserys to "imbue him with sincerity and realness". He also explained that acting as a character who is sick caused oxygen levels in his body to decrease, as he was "nearly passing out from doing those things." Considine was credited on the main cast for season 1, excluding the season finale "The Black Queen". In season 2, he made two uncredited guest appearances in the episodes "Smallfolk" and "The Red Sowing".

=== Intramural and extramural research === In 2019, the NIH devoted 10% of its funding to research within its own facilities (intramural research), and gave >80% of its funding in research grants to extramural (outside) researchers. Of this extramural funding, a certain percentage (2.8% in 2014) must be granted to small businesses under the SBIR/STTR program. As of 2011, the extramural funding consisted of about 50,000 grants to more than 325,000 researchers at more than 3000 institutions. By 2018, this rate of granting remained reasonably steady, at 47,000 grants to 2,700 organizations. In FY 2010, the NIH spent US$10.7bn (not including temporary funding from the American Recovery and Reinvestment Act of 2009) on clinical research, US$7.4bn on genetics-related research, US$6.0bn on prevention research, US$5.8bn on cancer, and US$5.7bn on biotechnology.

It is critical that the sample be processed before entering the mass spectrometer so that only a single chemical species enters at a given time. Generally, samples are combusted or pyrolyzed and the desired gas species (usually hydrogen (H2), nitrogen (N2), carbon dioxide (CO2), or sulfur dioxide (SO2)) is purified by means of traps, filters, catalysts and/or chromatography. The two most common types of IRMS instruments are continuous flow and dual inlet. In dual inlet IRMS, purified gas obtained from a sample is alternated rapidly with a standard gas (of known isotopic composition) by means of a system of valves, so that a number of comparison measurements are made of both gases. In continuous flow IRMS, sample preparation occurs immediately before introduction to the IRMS, and the purified gas produced from the sample is measured just once. The standard gas may be measured before and after the sample or after a series of sample measurements. While continuous-flow IRMS instruments can achieve higher sample throughput and are more convenient to use than dual inlet instruments, the yielded data is of approximately 10-fold lower precision.

Sources: en.wikipedia.org

Background from the literature

This refrigeration method cools a contained area by melting ice, by sublimating dry ice, or evaporating liquid nitrogen. A simple example of this is a portable cooler, where ice is poured over the items that need to be refrigerated, keeping them cool and insulated from heat. Regular ice maintains freezing temperatures, but not below the freezing point, unless salt is used to cool the ice down further (as in a traditional ice-cream maker). Mixtures of other solvents with coolants like water ice, dry ice, or liquid nitrogen are also used to make cooling baths for chemistry. Dry ice can reliably bring the temperature well below the freezing point of water, to as low as 195K.

=== Improved radial tires === Goodyear Tire and Rubber Company developed a fibrous material, five times stronger than steel, for NASA to use in parachute shrouds to soft-land the Viking Lander spacecraft on the Martian surface. Recognizing the durability of the material, Goodyear expanded the technology and went on to produce a new radial tire with a tread life expected to be 10,000 miles (16,000 km) greater than conventional radials.

The division is heir to the Blue Division which fought during the Franco-Prussian War of 1870, in particular during the Battle of Bazeilles and the 9th Colonial Infantry Division, part of the Free French Forces, which distinguished themselves in the apprehending of Elba in June 1944 and the disembarking in Provence on 15 August of the same year. The Division then made way to Indochina, where it was placed dormant (without being dissolved) in December 1947. The unit was reactivated in July 1963 in Brittany under the designation of 9th Brigade. On 1 January 1976, the division was baptized as 9th Marine Infantry Division 9e DIMa. Accordingly, the division was attached to the terrestrial intervention force, then the Rapid Action Force (FAR) since 1983. On 1 July 1999, the unit was restructured in a brigade and was designated as 9th Light Armoured Marine Brigade (BLBMa). On 1 January 2013, the brigade was named to the current designation as the 9th Marine Infantry Brigade (9e BIMa). The headquarter staff is stationed in Poitiers since 1 July 2010. The motto of the brigade is "Semper et Ulbique", Latin for "Always and All over". The "9th" illustrated capability on all exterior theatres of operations where France has been engaged since World War II: Indochina, Lebanon, Kuwait, Macedonia, Kosovo, Bosnia, Congo, Tchad, Ivory Coast.

There are a number of mechanisms through which religion may make a person happier, including social contact and support that result from religious pursuits, the mental activity that comes with optimism and volunteering, learned coping strategies that enhance one's ability to deal with stress, and psychological factors such as "reason for being." It may also be that religious people engage in behaviors related to good health, such as less substance abuse, since the use of psychotropic substances is sometimes considered abuse. The Handbook of Religion and Health describes a survey by Feigelman (1992) that examined happiness in Americans who have given up religion, in which it was found that there was little relationship between religious disaffiliation and unhappiness. A survey by Kosmin & Lachman (1993), also cited in this handbook, indicates that people with no religious affiliation appear to be at greater risk for depressive symptoms than those affiliated with a religion. A review of studies by 147 independent investigators found, "the correlation between religiousness and depressive symptoms was -.096, indicating that greater religiousness is mildly associated with fewer symptoms." The Legatum Prosperity Index reflects the repeated finding of research on the science of happiness that there is a positive link between religious engagement and well-being: people who report that God is very important in their lives are on average more satisfied with their lives, after accounting for their income, age and other individual characteristics.

Bukele began dating psychologist and former ballet dancer Gabriela Rodríguez in 2004 and the two married on 6 December 2014. The couple have two daughters. Their first was born in 2019 and their second in 2023.

Sources: en.wikipedia.org

Frequently asked questions

Is AOD-9604 approved for medical use?

No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.

Why is it banned in sports?

The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.

How is AOD-9604 detected?

Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.

Is AOD-9604 the same as human growth hormone?

No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.

Network